Cytokine release syndrome (CRS) is a relatively well-described toxicity of CAR T-cell therapy. However, their may be delayed manifestations of…
Browsing: Acute Lymphoblastic Leukemia
With CAR T-cell therapy, similarly to traditional chemotherapy, the use of a single agent will not remain effective in treating…
CAR T-cell therapy development is progressing across a wide range of hematological malignancies, with the results highly anticipated in acute…
An exciting new CAR T-cell product, which targets SLAMF7 (CS1, CD319), is displaying exciting preliminary results against multiple myeloma (MM)…
A major concern surrounding novel therapeutics is their safety, which must be characterized thoroughly. Here, Sattva Neelapu, MD, from the…
The latest CAR T-cell data was highly anticipated at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition…
Chimeric antigen receptor (CAR) T-cell therapy has been receiving buzz as a promising treatment for cancer patients. So which CAR…
Whats the latest information about MPN treatment and research? As part of our ASH 2017 coverage, Dr. John Crispino and…
What does the future of treatment for mantle cell lymphoma look like? From the 2017 American Society of Hematology (ASH)…
Whats the latest news on CAR-T cell therapy from the American Society Hematology (ASH) conference 2017 as we report on…
As part of our coverage of the 2017 American Society of Hematology (ASH) meeting in Atlanta, Dr. Srdan Verstovsek, an…
Will flow be the method used for myeloma treatment in the long term? Does transplant still have a role in…
Whats the latest in mantle cell lymphoma research? Esther Schorr, on location at the 2017 American Society of Hematology (ASH)…
As part of our coverage from the 2017 American Society of Hematology (ASH) annual meeting, A super panel of MPN…
Patient Power founders Andrew and Esther Schorr are joined by MPN expert Dr. Naveen Pemmaraju of MD Anderson Cancer Center,…
Roy S. Herbst, MD, PhD of Yale Cancer Center talks about EGFR inhibitor resistant patients and how EGFR antibodies may…
Roy S. Herbst, MD, PhD of Yale Cancer Center discusses EGFR small molecules versus antibodies in combination antibodies better than…
Jun J. Mao, MD of Memorial Sloan Kettering Cancer Center explains why oncologic supplements and diet correlative evidence is incomplete…
Roy S. Herbst, MD, PhD of Yale Cancer Center discusses how the FLAURA data & Osimertinib result in high PFS…
Jun J. Mao, MD of Memorial Sloan Kettering Cancer Center discusses how physical activity and fitness help lung cancer patients…
Jim L. Mulshine, MD of Rush University talks about the 2015 lung cancer screening data from the American Cancer Society,…
Jennifer S. Temel, MD of Mass General Hospital – Harvard Medical School explains how engaging patients talk about end of…
Roy S. Herbst, MD, PhD of Yale Cancer Center discusses lung cancer EGFR antibodies and where the research is going.…
Jun J. Mao, MD of Memorial Sloan Kettering Cancer Center discusses the definition of integrative oncology which they published a…
Jim L. Mulshine, MD of Rush University talks about computed tomography which can be used not just for lung cancer…
Daniel A. Pryma, MD of the University of Pennsylvania highlights one common question – when should a patient have his…
Jennifer S. Temel, MD of Mass General Hospital – Harvard Medical School discusses how involving palliative care earlier in the…
Roy S. Herbst, MD, PhD of Yale Cancer Center talks about possible flurry of activity that focuses on resistance to…
Jun J. Mao, MD of Memorial Sloan Kettering Cancer Center discusses how integrative medicine can improve health, quality of life,…
Jim L. Mulshine, MD of Rush University discusses costs of new lung cancer services and the aging population burdening current…
Paul K. Paik, MD of Memorial Sloan Kettering Cancer Center discusses Cobas EGFR mutation test v2 and the ability to…
Jennifer S. Temel, MD of Mass General Hospital – Harvard Medical School discusses how most patients prefer to die at…
Roy S. Herbst, MD, PhD of Yale Cancer Center discusses screening for EGFR mutation and why all lung cancers should…
Jun J. Mao, MD of Memorial Sloan Kettering Cancer Center discusses integrative oncology and how complementary therapy may be beneficial.…
Jim L. Mulshine, MD of Rush University explains that the national lung screening trial had a more diverse population than…
Daniel A. Pryma, MD of the University of Pennsylvania discusses how fluorodeoxyglucose (FDG) PET scan is still powerful tool for…
Jennifer S. Temel, MD of Mass General Hospital – Harvard Medical School discusses patient prognosis perception and how it impacts…
Roy S. Herbst, MD, PhD of Yale Cancer Center discusses squamous cell carcinoma 4+ EGFR and giving carboplatin cetuximab safely…
Jun J. Mao, MD of Memorial Sloan Kettering Cancer Center discusses a study where yoga may benefit cancer patients in…
Jim L. Mulshine, MD of Rush University discusses the veterans administration’s lung cancer pilot study that about 40% of scans…
Paul K. Paik, MD of Memorial Sloan Kettering Cancer Center discusses that there is short-term and long-term hope for squamous…
Daniel A. Pryma, MD of the University of Pennsylvania discusses the challenges of imaging immunotherapy for lung cancer. In the…
Jennifer S. Temel, MD of Mass General Hospital – Harvard Medical School discusses how prognosis, treatment goals and how end…
The stimulating area of CAR T-cell therapy is currently limited due to a range of factors, which must be overcome…
The efficacy results of the major CAR T-cells in development have been very positive. In this interview, Jeremy Abramson, MD,…
The assistance obtained from outside of GP clinics and hospitals is essential in the treatment of cancer patients. In this…
Supportive care is an essential element of the overall management of patients with cancer. Speaking from the British Oncology Pharmacy…
Carl Booth, MPhil BPharm MRPharmS, of Airedale NHS Foundation Trust, Keighley, UK provides an overview of the abstract selection process…
Carl Booth, MPhil BPharm MRPharmS, of Airedale NHS Foundation Trust, Keighley, UK talks to us about the key topics presented…
Carl Booth, MPhil BPharm MRPharmS, of Airedale NHS Foundation Trust, Keighley, UK, talks to us about collaboration amongst pharmacists to…